Format

Send to

Choose Destination
See comment in PubMed Commons below
Dement Geriatr Cogn Disord. 2007;23(6):401-5. Epub 2007 Apr 3.

Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.

Author information

1
Alzheimer's Diagnostic and Treatment Center, Bennington, VT 05201, USA. kedwards@vtneuro.com

Abstract

BACKGROUND:

Dementia with Lewy bodies (DLB) is a common dementia of the elderly. A significant cholinergic deficit has been demonstrated that may be responsive to treatment by cholinesterase inhibitors (ChEIs).

METHODS:

A 24-week, open-label study was designed to assess the efficacy and safety of a ChEI, galantamine, in 50 patients with DLB.

RESULTS:

This study showed beneficial effects with galantamine in 2 of the 3 primary efficacy parameters. The scores on the Neuropsychiatric Inventory (NPI-12) improved by 8.24 points from baseline (p = 0.01) especially in visual hallucinations and nighttime behaviors (p = 0.004). The scores on the Clinician's Global Impression of Change improved by 0.5 points from baseline (p = 0.01). The third primary efficacy parameter, the Cognitive Drug Research Computerized Cognitive Assessment System, was unchanged from baseline. Adverse events were generally mild and transient.

CONCLUSION:

Galantamine appears to be an effective and safe therapy for patients with DLB.

PMID:
17409748
DOI:
10.1159/000101512
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center